Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker VERU · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Pati… NCT04842747 · SARS-CoV Infection VERU-111 | VERU Veru Inc. | Phase 3 | Completed | 204 | Jul 6, 2022 | Registry ↗ |
| Sep 4, 2026 | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Pat… NCT07446998 · Obesity & Overweight, Mobility Disability Enobosarm, Semaglutide (Wegovy) weekly injection | VERU Veru Inc. | Phase 2 | Active, not recruiting | 239 | Oct 2027 | Registry ↗ |
| Sep 17, 2025 | Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 fo… NCT06282458 · Muscle Loss, Obesity Enobosarm, Semaglutide | VERU Veru Inc. | Phase 2 | Completed | 168 | Apr 11, 2025 | Registry ↗ |
| Feb 26, 2024 | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metast… NCT05065411 · Metastatic Breast Cancer Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroid… | VERU Veru Inc. | Phase 3 | Terminated | 5 | Oct 19, 2023 | Registry ↗ |
| Feb 5, 2024 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Recepto… NCT04844749 · Metastatic Castration-resistant Prostate Cancer, Androgen R… VERU-111, Enzalutamide, Abiraterone | VERU Veru Inc. | Phase 3 | Terminated | 105 | May 4, 2023 | Registry ↗ |
| Jan 26, 2024 | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer NCT04869943 · Metastatic Breast Cancer Enobosarm, Exemestane | VERU Veru Inc. | Phase 3 | Terminated | 52 | Jan 9, 2024 | Registry ↗ |
| Sep 26, 2023 | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistan… NCT03752099 · Metastatic Castration Resistant Prostate Cancer VERU-111 | VERU Veru Inc. | Phase 1/2 | Terminated | 80 | Mar 15, 2023 | Registry ↗ |
| May 19, 2023 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer NCT04843319 · Advanced Prostate Adenocarcinoma VERU-100 | VERU Veru Inc. | Phase 1/2 | Terminated | 24 | Jan 19, 2023 | Registry ↗ |
| Mar 24, 2023 | Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Meta… NCT05079360 · Metastatic Breast Cancer Sabizabulin, Exemestane monotherapy, exemestane plus everol… | VERU Veru Inc. | Phase 2 | Withdrawn | 0 | Mar 30, 2024 | Registry ↗ |
| Oct 27, 2022 | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 NCT04388826 · Respiratory Distress Syndrome, Adult Veru-111 | VERU Veru Inc. | Phase 2 | Completed | 39 | Dec 18, 2020 | Registry ↗ |
| Feb 8, 2022 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo T… NCT05008510 · Metastatic Triple Negative Breast Cancer Sabizabulin, Sacituzumab Govitecan-hziy | VERU Veru Inc. | Phase 2 | Withdrawn | 0 | Jul 30, 2022 | Registry ↗ |
| Dec 3, 2021 | Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer NCT03646162 · Prostate Cancer Metastatic Veru-944, Placebo | VERU Veru Inc. | Phase 2 | Completed | 93 | Apr 30, 2020 | Registry ↗ |
12 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances